Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of AP301 for control of serum phosphorus in dialysis patients with chronic kidney disease and hyperphosphatemia
CTR20231624Phase 3Completed
- Sponsor
- Likang Life Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AP301 in hyperphosphatemia, sponsored by Likang Life Sciences. Started Jun 2023; status: completed.
02
Drugs
AP301
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on CTR20231624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231624.